Imatinib or transplant for chronic myeloid leukaemia? [7] (multiple letters)

Lancet

Volumn 362, Issue 9378, 2003, Pages 172-173

  Goldman, John ^a   Apperley, Jane ^a   Kanfer, Edward ^a   Olavarria, Eduardo ^a   Marin, David ^a   Craddock, C ^b   Augustson, B ^b   Basu, S ^b,c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ALLOTRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DONOR; DRUG EFFICACY; FOLLOW UP; HLA SYSTEM; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; REDUCTION; RELAPSE; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0038643673     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13879-2     Document Type: Letter

References (5)

1. EA Sausville Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard? Lancet 361 2003 1400 1401
2. R Or MY Shapira I Resnick Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Blood 101 2003 441 445
3. M Uzunel J Mattsson M Brune J-E Johansson O Ringden Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after non-myeloablative conditioning and allogeneic stem cell transplantation Blood 101 2003 469 472
4. A Gratwohl J Hermans JM Goldman Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation Lancet 352 1998 1087 1092
5. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 1001; 98: 2039–42.